摘要
目的观察米非司酮治疗子宫肌瘤对子宫内膜组织形态和内膜中雌激素受体（ER）、孕激素受体（PR）的影响。方法米非司酮组为20例临床诊断为子宫肌瘤合并不同程度贫血，有手术指征的患者，从月经第1天起给予米非司酮12．5mg／d口服，连续30d，第31～91天8mg／d口服。停药后立即手术；对照组为同期手术的36例未服用米非司酮的子宫肌瘤患者。两组手术后子宫标本均采用ER，PR单克隆抗体免疫组织化学法检测子宫内膜的ER，PR表达。结果米非司酮组子宫内膜以增殖期变化为主，内膜的ER，PR表达处于早、中增殖期水平。结论小剂量米非司酮治疗子宫肌瘤对子宫内膜是安全的，并不会增加其癌变倾向。
Objective Observing the change of histomorphology and the positive rates of estrogen receptors （ ER ）, progesten receptors （ PR） of endometrium after mifepristone treatment. Methods Twenty patients with uterine myoma complicated with anemia received 12.5 mg of mifepristone daily for 30 days beginning on the first day of menstrual cycle,8mg daily for another 60 days. Hysterectomy was performed just when the treatment finished. Control group included 36 patients sufferes from leomyomas with no mifepristone treatmen. At the beginning and the end of treatment,we monitored the changes of the uterus and the lagest myoma with B-us and gynecological examinations. Endometrium tissue were obtained for immunohistochemical ER,PR analyses using monoclonal antibody. Results Proliferative changes were observed in most of the endometrium of study group,the expression of ER,PR was in a early proliferating level. Conclusion The effect on endometrium is safe.
出处
《潍坊医学院学报》
2008年第2期103-105,共3页
Acta Academiae Medicinae Weifang
